Timothy M. Piser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Timothy M. Piser has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Amanda Ellis
Departments of Neuroscience and Molecular Sciences, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850
1 shared publicationAnna Zacco
Department of Neuroscience, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
1 shared publicationDarlene Lloyd
Departments of Neuroscience and Molecular Sciences, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850
1 shared publicationJames Togo
Departments of Neuroscience and Molecular Sciences, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850
1 shared publicationKatherine Spence
Departments of Neuroscience and Molecular Sciences, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850
1 shared publicationSteve Furlong
Departments of Neuroscience and Molecular Sciences, CNS Discovery Research, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850
1 shared publication
Latest Publications
- 1 May 2010
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 24 (4) , 515-524
Linking the cytokine and neurocircuitry hypotheses of depression: A translational framework for discovery and development of novel anti-depressants
- 1 May 2010
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 24 (4) , 515-524
Linking the cytokine and neurocircuitry hypotheses of depression: A translational framework for discovery and development of novel anti-depressants
- Open Access
- 3 December 2003
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 23 (35) , 11104-11111
3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity
3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, reduce the incidence of strokes and reduce infarct volume after cerebral ischemia in mice. Excitoxicity caused by overstimulation of glutamate receptors is a major cause of neuronal death after an ischemic brain insult. Experiments presented here explored whether statins protect cultured neurons from excitotoxic death caused by the glutamate receptor agonist NMDA. Treatment with statins preserved NMDA receptor-expressing cortical neurons and potently and substantially reduced lactate dehydrogenase release caused by exposure of embryonic mouse neocortical cultures to NMDA. The rank order of neuroprotective potency was rosuvastatin = simvastatin > atorvastatin = mevastatin > pravastatin, which is similar to the known rank order of potency for inhibition of the HMG-CoA reductase enzyme. Resistance of cultures to NMDA excitotoxicity developed after several days of statin exposure. Neuroprotection by rosuvastatin was coincident with a decrease in cell sterols and occurred with a similar potency as inhibition of cholesterol biosynthesis. Neuroprotection was substantially attenuated by cotreatment with either mevalonate or cholesterol and was mimicked by acute treatment with the cholesterol-extracting agent β-cyclodextrin, suggesting that neuroprotection was mediated by depletion of a cellular pool of cholesterol because of the inhibition of cholesterol biosynthesis. These results suggest the possibility that, in addition to effects on cerebrovascular function, statins have the potential to render cortical neurons more resistant to NMDA-induced excitotoxic death as a result of changes in cell cholesterol homeostasis.
- 3 December 2003
- Published by Society for Neuroscience in The Journal of Neuroscience
- Vol. 23 (35) , 11104-11111
Open Access3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Protect Cortical Neurons from Excitotoxicity
3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, reduce the incidence of strokes and reduce infarct volume after cerebral ischemia in mice. Excitoxicity caused by overstimulation of glutamate receptors is a major cause of neuronal death after an ischemic brain insult. Experiments presented here explored whether statins protect cultured neurons from excitotoxic death caused by the glutamate receptor agonist NMDA. Treatment with statins preserved NMDA receptor-expressing cortical neurons and potently and substantially reduced lactate dehydrogenase release caused by exposure of embryonic mouse neocortical cultures to NMDA. The rank order of neuroprotective potency was rosuvastatin = simvastatin > atorvastatin = mevastatin > pravastatin, which is similar to the known rank order of potency for inhibition of the HMG-CoA reductase enzyme. Resistance of cultures to NMDA excitotoxicity developed after several days of statin exposure. Neuroprotection by rosuvastatin was coincident with a decrease in cell sterols and occurred with a similar potency as inhibition of cholesterol biosynthesis. Neuroprotection was substantially attenuated by cotreatment with either mevalonate or cholesterol and was mimicked by acute treatment with the cholesterol-extracting agent β-cyclodextrin, suggesting that neuroprotection was mediated by depletion of a cellular pool of cholesterol because of the inhibition of cholesterol biosynthesis. These results suggest the possibility that, in addition to effects on cerebrovascular function, statins have the potential to render cortical neurons more resistant to NMDA-induced excitotoxic death as a result of changes in cell cholesterol homeostasis.